Skip to main content
Evidence Snapshot

Nitric oxide synthase, inducible

CHEMBL4481 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:46Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4481
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Nitric oxide synthase, inducible as ChEMBL target CHEMBL4481, mapped to UniProt P35228. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Nitric oxide synthase, inducible
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL4481
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P35228
Nitric oxide synthase, inducible
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Nitric oxide synthase, inducible matters

As of 2026-09-14

Nitric oxide synthase, inducible is reviewed as Nitric oxide synthase, inducible (UniProt P35228); Nitric oxide synthase, inducible shows clinical signal disease relevance led by migraine disorder. 2 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 1 approved drug, 1517 compounds, and 195 assays, with lead potency reaching pChEMBL 9.9.

Disease context
migraine disorder

Nitric oxide synthase, inducible shows clinical signal disease relevance led by migraine disorder. 2 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 2 additional disease programs remain visible in the same card. Linked drugs include GW-274150.

Start review with migraine disorder because it currently carries clinical signal support. Linked drugs include GW-274150. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Clinical signal 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 1 approved drug, 1517 compounds, and 195 assays for this target. The dominant activity type is IC50. CHEMBL220632 is the current potency anchor at pChEMBL 9.9.

Use CHEMBL220632 as the tractability anchor when discussing potency (pChEMBL 9.9).

Activity source · ChEMBL 36 via Core Engine
1 approved pChEMBL 9.9
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Nitric oxide synthase, inducible matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P35228, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why migraine disorder is currently treated as clinical signal support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1517
Total Compounds
195
Total Assays
1
Approved Drugs
IC50: 1093.0, KI: 254.0, EC50: 122.0, KD: 17.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL220632
 9.9 IC50 —
No preferred name
CHEMBL220880
 9.9 IC50 —
No preferred name
CHEMBL1093059
 9.7 IC50 Clinical
No preferred name
CHEMBL385324
 9.6 IC50 —
No preferred name
CHEMBL376733
 9.6 IC50 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:46Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4481